Navigation Links
ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
Date:1/7/2009

FREDERICK, Md., Jan. 7 /PRNewswire/ -- ImQuest Life Sciences announced today the successful submission of an IND application to the Food and Drug Administration to initiate human clinical trials for their lead pyrimidinedione HIV inhibitor IQP-0410. ImQuest anticipates initiating their Phase 1 studies in the first quarter of 2009. IQP-0410 is a novel small molecule inhibitor of HIV which primarily acts as a nonnucleoside reverse transcriptase inhibitor (NNRTI). The compound possesses a second mechanism of action which prevents the entry of HIV into target cells and significantly raises the potential genetic barrier to resistance with IQP-0410 therapy. Preclinical pharmacokinetic and toxicology studies have demonstrated the potential for once per day dosing and a high safety margin for the compound. IQP-0410 has been found to inhibit HIV replication at sub-nanomolar concentration levels and to have highly significant activity against all clinical virus strains evaluated as well as against multi-drug resistant virus strains obtained from patients failing long courses of therapy with currently approved RT and protease inhibitors. The compound is well suited for use as a component of primary HAART regimens as well as a salvage therapy option. Preclinical studies have also demonstrated the ability of the compound to be used in combination with all other approved HIV drugs.

"The submission of this IND represents a critical milestone in the therapeutic development of the pyrimidinedione class of molecules as potential new HIV drugs and an important success in the strategic drug development initiatives between ImQuest and Samjin Pharmaceutical Co. Ltd of Seoul, KOREA," said Dr. Robert W. Buckheit, Jr., Executive Vice President and Chief Scientific Officer of ImQuest Life Sciences. "We believe that IQP-0410 will be a new and novel addition to the armamentarium of HIV drugs available and provide HIV-infected individuals with a safe and effective alter
'/>"/>

SOURCE ImQuest Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
2. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
3. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
4. Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
5. U.S. Naval Medical Research Center Resubmits IND Application for Proposed Op RESUS Clinical Trial in Trauma Patients in the Battlefield Setting
6. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
7. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
8. U.S. Navy Submits Protocol for Field Trauma Trial of Hemopure(R)
9. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
10. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
11. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 At the 2015 ... Association recognized 15 winners in the categories of ... across multiple vertical markets. ContextMedia:Health proudly took ... for its success with its first-to-market Patient ... ContextMedia:Health, the leading provider of digital solutions ...
(Date:7/28/2015)... July 28, 2015  For many medical institutions and ... and other inventors can be a constant challenge. Taking ... and successes are rare. A new company ... that. Medical Device Investments (MDI) was created ... hospitals and physicians. MDI develops, manufactures and markets the ...
(Date:7/28/2015)... Transparency Market Research (TMR) has announced ... Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, ... to this report, the global cancer diagnostics market is expected ... period of 2014 to 2020. In 2013, the global cancer ... to be worth US$168,649.3 million by 2020.The increasing prevalence of ...
Breaking Medicine Technology:ContextMedia:Health Receives Top Award at the ICX Association Excellence Awards 2Medical Device Investments To Become Center Of Excellence For The Commercialization Of Innovative Medical Technologies 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 3Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 4
... Alcona Health Center is one of the first organizations ... payment after successfully meeting the requirements for Year One ... Alcona Health received a first-year incentive payment for each ... Medicare and Medicaid Services, resulting in one of the ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), ... that Jeffrey H. Burbank, Chief Executive Officer, will present ... September 20th, at 3:00 p.m. ET.   A webcast ... http://www.nxstage.com/ir.cfm at the time of the presentation. ...
Cached Medicine Technology:SuccessEHS Client Among First in State of Michigan to Receive Medicaid Stimulus Funds 2SuccessEHS Client Among First in State of Michigan to Receive Medicaid Stimulus Funds 3SuccessEHS Client Among First in State of Michigan to Receive Medicaid Stimulus Funds 4
(Date:7/28/2015)... ... July 28, 2015 , ... ... with 1 in 68 children currently affected with the disorder. For these families, ... the road to recovery is extremely daunting. That’s where Talk About Curing Autism ...
(Date:7/28/2015)... ... July 28, 2015 , ... DuPont leaders today ... Ethiopia to learn more about the impact of U.S. collaborations with local partners ... on accelerating agricultural development as an engine of broad-based economic growth in the ...
(Date:7/28/2015)... Miami, FL (PRWEB) , ... July 16, 2015 ... ... Multi-line Insurance Agency, in Miami, FL, that specializes in providing Health insurance quotes ... With multiple carriers clients compare auto insurance rates that best suits their specific ...
(Date:7/28/2015)... ... July 28, 2015 , ... Women in Technology (WIT), the ... community for over 20 years, has selected Lisa Dezzutti, CEO and president at Market ... “I am excited to serve this organization that empowers women to thrive and excel ...
(Date:7/28/2015)... FL (PRWEB) , ... July 28, 2015 , ... Dr. ... diseases. , The talk took place from noon to 1 p.m. Tuesday, June 23, ... Panama City, Fla. , Dr. Ahmad is board-certified in colorectal surgery and has ...
Breaking Medicine News(10 mins):Health News:National TACA Autism Conference Offers Hope and Help to Families Affected by Autism 2Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 2Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 3Health News:US President learns from DuPont Innovations in Food and Agriculture in Ethiopia 4Health News:Nations Insurance Solutions Announces Auto, Motorcycle, and Commercial Business Insurance Quotes. 2Health News:Lisa Dezzutti Named President of Women in Technology (WIT) Board of Directors 2Health News:Dr. Aziz Ahmad Delivers Talk at Gulf Coast Medical Center 2
... of Oracle Content Management Leads to Increased Footprint Supporting ... ... Multiple Business Units, REDWOOD SHORES, Calif., Feb. ... and largest integrated,not-for-profit medical group practice in the world, is ...
... (Amex: PTN ) announced today financial results for ... net loss of $3.8 million, or,($0.04) per basic and ... to a net loss of $6.5 million, or ($0.09) ... 2006. Total revenues for the quarter,ended December 31, 2007 ...
... LONDON, February 11 Amarin Corporation plc,(NASDAQ: ... notification from The,Nasdaq Stock Market that the Company ... bid price requirement for continued listing on the ... In,the notification, Nasdaq advised that the Company has ...
... Transition Therapeutics Inc.,("Transition" or the "Company") (NASDAQ: TTHI ... February 12, 2008 at 5:00 P.M. EST to discuss,the ... Chairman,and Chief Executive Officer of the Company, will host ... period in a press release to,be issued prior to ...
... RALEIGH, N.C., Feb. 11 MedThink Communications, ... and,public relations, has been retained by Salix ... its newest product under development, an,orally disintegrating ... the rights to market the orally disintegrating,metoclopramide ...
... health care providers play a key role in the ... findings suggest that interventions targeting both the provider and ... rates, and in particular must take into account patient ... cancer will be discovered. The study is published in ...
Cached Medicine News:Health News:Oracle Helps Mayo Clinic Improve Information Management 2Health News:Oracle Helps Mayo Clinic Improve Information Management 3Health News:Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008 2Health News:Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008 3Health News:Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008 4Health News:Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008 5Health News:Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008 6Health News:Amarin Regains Compliance With Nasdaq Listing Requirements 2Health News:Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2008 Financial Results on Tuesday, February 12, 2008 at 5:00 P.M. EST 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 3Health News:Provider influence and patient barriers affect use of colorectal cancer screening 2
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Ideal for surgical procedures, these portable stands fit into tight areas for easy instrument access. Designed for limited space environments. Adjustable height for comfortable use while sitting or s...
... programmable memory two position control, illuminated ... sides, solid cast aluminum frame, armrest, ... headrest, securely locking hand brake with ... contoured cushions with anti-viral upholstery, self-lubricating ...
Complete with headrest, armrests, footrest and foot switch....
Medicine Products: